OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
PAVM
PAVmed Inc.
There isn't enough reported data to score PAVM yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
PAVM Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Under pressure | |
| Unavailable |
PAVM's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
PAVM PE Valuation
PAVM has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
PAVM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect PAVM's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the stronger earnings trend. Trailing diluted EPS is up 147% for OSCR versus PAVM down 107%.
PAVM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$129.90 | +$189.83 |
| Q2 2024 | -$245.10 | +$133.13 |
| Q1 2024 | -$272.40 | +$173.33 |
| Q4 2023 | -$274.80 | +$179.93 |
| Q3 2023 | -$319.73 | +$134.77 |
| Q2 2023 | -$378.23 | +$13.27 |
| Q1 2023 | -$445.73 | -$121.73 |
| Q4 2022 | -$454.73 | -$162.23 |
PAVM is still losing money, but far less than before: $16.54 per share over the past year, against $454.73 at its worst in late 2022.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over PAVM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over PAVM on profitability, with a higher operating margin.
PAVM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $33K | +450% |
| Q1 2026 | $22K | +175% |
| Q3 2025 | $5K | -100% |
| Q2 2025 | $6K | -99% |
| Q1 2025 | $8K | -99% |
| Q3 2024 | $1M | +26% |
| Q2 2024 | $1M | +502% |
| Q1 2024 | $1M | +124% |
PAVM's revenue is recovering but still below its 2023 peak: $33,000 last quarter, up 450% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -21279% | +57305 points |
| Q1 2026 | -36523% | +31552 points |
| Q4 2025 | -13083% | N/A |
| Q3 2025 | -96880% | -95722 points |
| Q2 2025 | -78583% | -77215 points |
| Q1 2025 | -68075% | -66671 points |
| Q3 2024 | -1158% | +805 points |
| Q2 2024 | -1368% | +8562 points |
PAVM's operating margin was −21279% last quarter, up 57305 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over PAVM on cash generation, producing positive trailing cash flow while its opponent burns cash.
PAVM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.7M | -$1.5M |
| Q1 2026 | -$2.6M | -$1.1M |
| Q4 2025 | -$1.6M | -1839% |
| Q3 2025 | -$899K | +$8M |
| Q2 2025 | -$1.2M | +$10.5M |
| Q1 2025 | -$1.6M | +$11.6M |
| Q4 2024 | $90K | +$12.1M |
| Q3 2024 | -$8.9M | +$2.2M |
PAVM has burned cash in almost every quarter: −$8M over the past year, against −$12M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over PAVM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
PAVM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +297% | +4.7M shares |
| 1 year | +940% | +5.7M shares |
| 3 years | +3067% | +6.1M shares |
| 5 years | +5731% | +6.2M shares |
| Available history | +8992% | +6.2M shares |
PAVM has 6M diluted shares, up 940% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
PAVM Net Leverage
PAVM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
PAVM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 21.8 | Oversold |
| Stochastic | 2.5 | Oversold |
PAVM's weekly RSI is 22 (oversold) and its Stochastic is 3 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
PAVM PE vs Healthcare Sector
PAVM has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over PAVM on trend strength, trading above more of its moving averages.
PAVM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.37 | 43% below |
| 20 week MA | $3.97 | 66% below |
| 50 week MA | $6.56 | 80% below |
| 100 week MA | $12.0 | 89% below |
| 200 week MA | $59.1 | 98% below |
PAVM is in a downtrend: it's below all five of its weekly moving averages, and 98% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over PAVM on returns for 2026, with the stronger performance.
PAVM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $517.5 | $877.5 | +70% |
| 2021 | $877.5 | $1,242.0 | +42% |
| 2022 | $1,242.0 | $227.3 | -82% |
| 2023 | $227.3 | $123.6 | -46% |
| 2024 | $123.6 | $19.4 | -84% |
| 2025 | $19.4 | $8.68 | -55% |
| 2026 YTD | $8.68 | $1.34 | -85% |
PAVM has finished four years in a row lower, and it's down 85% so far in 2026.